Summary
26.46 0.03(0.11%)10/04/2024
Myriad Genetics, Inc. (MYGN)
Myriad Genetics, Inc. (MYGN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.11 | 0.00 | 4.15 | 6.27 | 31.05 | 68.97 | -8.51 | 442.86 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 26.46 | |
| Open | 26.77 | |
| High | 27.03 | |
| Low | 26.31 | |
| Volume | 280,539 | |
| Change | -0.03 | |
| Change % | -0.11 | |
| Avg Volume (20 Days) | 419,622 | |
| Volume/Avg Volume (20 Days) Ratio | 0.67 | |
| 52 Week Range | 13.82 - 29.30 | |
| Price vs 52 Week High | -9.69% | |
| Price vs 52 Week Low | 91.46% | |
| Range | -1.16 | |
| Gap Up/Down | -0.49 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,382 | |
| EBIDTA | -67,800,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 1.4001 | |
| WallStreet Target Price | 24.82 | |
| Book Value | 8.3980 | |
| Earnings Per Share | -2.8000 | |
| EPS Estimate Current Quarter | 0.0100 | |
| EPS Estimate Next Quarter | -0.0400 | |
| EPS Estimate Current Year | -0.3000 | |
| EPS Estimate Next Year | -0.0100 | |
| Diluted EPS (TTM) | -2.8000 | |
| Revenues | ||
| Profit Marging | -0.3030 | |
| Operating Marging (TTM) | -0.1380 | |
| Return on asset (TTM) | -0.0660 | |
| Return on equity (TTM) | -0.2941 | |
| Revenue TTM | 774,200,000 | |
| Revenue per share TTM | 9.1140 | |
| Quarterly Revenue Growth (YOY) | 0.1160 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 476,400,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 2,000.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.2434 | |
| Revenue Enterprise Value | 2.3477 | |
| EBITDA Enterprise Value | -8.9577 | |
| Shares | ||
| Shares Outstanding | 90,508,000 | |
| Shares Float | 70,811,634 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.09 | |
| Insider (%) | 2.35 | |
| Institutions (%) | 103.48 | |
10/03 09:00 EST - globenewswire.com
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
SALT LAKE CITY and FREMONT, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput next-generation sequencing (NGS) platform, today announced a joint effort to explore Ultima's UG 100™ sequencing platform and its ppmSeq™ technology to advance Myriad's ability to offer groundbreaking clinical tests. Myriad has purchased a new UG 100 that will soon join other leading sequencing platforms in its new Lab of the Future facility in South San Francisco.
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
SALT LAKE CITY and FREMONT, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput next-generation sequencing (NGS) platform, today announced a joint effort to explore Ultima's UG 100™ sequencing platform and its ppmSeq™ technology to advance Myriad's ability to offer groundbreaking clinical tests. Myriad has purchased a new UG 100 that will soon join other leading sequencing platforms in its new Lab of the Future facility in South San Francisco.
10/01 16:05 EST - globenewswire.com
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a third patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a third patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.
10/01 12:46 EST - zacks.com
BMRN or MYGN: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and Myriad Genetics (MYGN). But which of these two companies is the best option for those looking for undervalued stocks?
BMRN or MYGN: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with BioMarin Pharmaceutical (BMRN) and Myriad Genetics (MYGN). But which of these two companies is the best option for those looking for undervalued stocks?
09/18 10:56 EST - zacks.com
Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
09/17 10:25 EST - zacks.com
Should You Continue to Retain MYGN Stock in Your Portfolio?
Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.
Should You Continue to Retain MYGN Stock in Your Portfolio?
Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.
09/04 12:41 EST - zacks.com
New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues
MYGN focuses on effective capital deployment in key areas, including new tech-enabled tools and capabilities, innovation and commercial capabilities.
New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues
MYGN focuses on effective capital deployment in key areas, including new tech-enabled tools and capabilities, innovation and commercial capabilities.
08/30 10:50 EST - zacks.com
Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
08/21 08:00 EST - globenewswire.com
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in two upcoming investor healthcare conferences.
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in two upcoming investor healthcare conferences.
08/09 11:20 EST - seekingalpha.com
Myriad Genetics, Inc. (MYGN) Q2 2024 Earnings Call Transcript
Myriad Genetics, Inc. (NASDAQ:MYGN ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Matt Scalo - Senior Vice President-Investor Relations Paul Diaz - President & Chief Executive Officer Mark Verratti - Chief Commercial Officer Sam Raha - Chief Operating Officer Scott Leffler - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Colleen Babington - Wolfe Research Andrew Cooper - Raymond James Casey Woodring - JPMorgan Puneet Souda - Leerink Partners Kyle Boucher - TD Cowen Operator Good day, and thank you for standing by. Welcome to the Myriad Genetics Second Quarter 2024 Financial Earnings Conference Call.
Myriad Genetics, Inc. (MYGN) Q2 2024 Earnings Call Transcript
Myriad Genetics, Inc. (NASDAQ:MYGN ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Matt Scalo - Senior Vice President-Investor Relations Paul Diaz - President & Chief Executive Officer Mark Verratti - Chief Commercial Officer Sam Raha - Chief Operating Officer Scott Leffler - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Colleen Babington - Wolfe Research Andrew Cooper - Raymond James Casey Woodring - JPMorgan Puneet Souda - Leerink Partners Kyle Boucher - TD Cowen Operator Good day, and thank you for standing by. Welcome to the Myriad Genetics Second Quarter 2024 Financial Earnings Conference Call.
08/08 09:21 EST - zacks.com
Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised
Myriad Genetics (MYGN) delivers a strong performance across its portfolio in the second quarter of 2024 and increases its long-term revenue growth rate target.
Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised
Myriad Genetics (MYGN) delivers a strong performance across its portfolio in the second quarter of 2024 and increases its long-term revenue growth rate target.
08/06 20:00 EST - zacks.com
Myriad (MYGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Myriad (MYGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
08/06 19:31 EST - zacks.com
Myriad Genetics (MYGN) Surpasses Q2 Earnings and Revenue Estimates
Myriad Genetics (MYGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.08 per share a year ago.
Myriad Genetics (MYGN) Surpasses Q2 Earnings and Revenue Estimates
Myriad Genetics (MYGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.08 per share a year ago.
08/02 01:30 EST - globenewswire.com
EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT® GENOMIC TEST FROM MYRIAD GENETICS
EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT ® GENOMIC TEST FROM MYRIAD GENETICS
EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT® GENOMIC TEST FROM MYRIAD GENETICS
EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT ® GENOMIC TEST FROM MYRIAD GENETICS
07/31 08:50 EST - globenewswire.com
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Jennifer Fox as Chief Legal Officer, effective September 3, 2024.
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Jennifer Fox as Chief Legal Officer, effective September 3, 2024.
07/18 12:40 EST - zacks.com
INCY or MYGN: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Incyte (INCY) and Myriad Genetics (MYGN). But which of these two companies is the best option for those looking for undervalued stocks?
INCY or MYGN: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Incyte (INCY) and Myriad Genetics (MYGN). But which of these two companies is the best option for those looking for undervalued stocks?
07/15 15:06 EST - zacks.com
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease. The idea is to broaden patient access to the benefits of MRD testing.
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease. The idea is to broaden patient access to the benefits of MRD testing.
07/11 09:00 EST - globenewswire.com
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The agreement helps solidify each company's freedom to operate in the MRD market and broadens patient access to the benefits of MRD testing.
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD). The agreement helps solidify each company's freedom to operate in the MRD market and broadens patient access to the benefits of MRD testing.
07/10 08:56 EST - zacks.com
Myriad Genetics (MYGN) Advances in MRD Space With New Patent
Myriad Genetics (MYGN) achieves a second foundational patent bolstering the MRD assay development.
Myriad Genetics (MYGN) Advances in MRD Space With New Patent
Myriad Genetics (MYGN) achieves a second foundational patent bolstering the MRD assay development.
07/02 09:00 EST - globenewswire.com
Myriad Genetics Earns 2024 Great Place To Work® Certification™
SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the second year in a row. The certification is based entirely on what current employees say about their experience working at Myriad. This year, 84% of employees said it's a Great Place To Work – 27 percentage points higher than the average U.S. company.
Myriad Genetics Earns 2024 Great Place To Work® Certification™
SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Certification for the second year in a row. The certification is based entirely on what current employees say about their experience working at Myriad. This year, 84% of employees said it's a Great Place To Work – 27 percentage points higher than the average U.S. company.
06/24 16:05 EST - globenewswire.com
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health